12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study [Gastrointestinal Cancer]

Conclusion
To our knowledge, this study provides the first validation of the 12-gene Recurrence Score assay in stage III colon cancer without chemotherapy and showed the heterogeneity of recurrence risks in stage III as well as in stage II colon cancer.

Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Yamanaka, Oki, Yamazaki, Yamaguchi, Muro, Uetake, Sato, Nishina, Ikeda, Kato, Kanazawa, Kusumoto, Chao, Lopatin, Krishnakumar, Bailey, Akagi, Ochiai, Ohtsu, Ohashi, Yoshino Tags: Gastrointestinal Cancer Source Type: research